posteditor

posteditor

Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

B LEXINGTON, Mass., April 14, 2026 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announces the submission of a supplemental Biologics… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

Why NetSuite Users Should Pay Attention to SensePass

Array “SensePass patented payment tag for in-person NetSuite payments”Salora ERP and SensePass have partnered to move payments from a back-office workaround to a strategic financial… Login to continue reading Login Sign up for complimentary access Sign Up Now Close